Low frequent HIV drug resistant polymorphisms in infants born to HIV sero-positive mothers: Implications on response to therapy

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201810587719948

Enrollment

260

Registered

2018-10-31

Start date

2017-09-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

HIV/AIDS

Interventions

Baseline HIV Drug resistance testing

No baseline line drug resistance testing

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: • Male or Female infant • Up to six months of age • Confirmed HIV positive test following DNA PCR • Has not been started on any combination antiretroviral therapy • Mother or care taker willing to consent for both her and the child

Exclusion criteria

Exclusion criteria: • Involvement in another study for the baby • Presence of any very serious illness • Any other documented medical illnesses that are not well controlled

Design outcomes

Primary

Measure	Time frame
Detection of a viral load greater than 1000 copies. These patients then based on the regimen they are taking, a drug resistance test will be done and switched to a regimen as dictated by the drug resistance results.	—

Secondary

Measure	Time frame
Determination of levels of adherence in patients with a detectable viral load greater than 1000 copies/ml.	—

Countries

Uganda

Contacts

Public ContactChristine Matama

Study coordinator

cmatama@jcrc.org.ug+256706445782

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026